AIMEDBIO, a biotech company specializing in antibody-drug conjugates (ADC), announced on November 25 that it achieved a subscription rate of 1,736.8 to 1 in its public offering for KOSDAQ listing, continuing its successful streak following robust demand forecasting.
According to Mirae Asset Securities, approximately 438,000 subscription applications were received from general investors during the public subscription period held from November 21 to November 24. The subscription deposit amounted to about 15.3552 trillion won, marking the largest scale among KOSDAQ IPOs this year.
In the earlier demand forecasting for institutional investors, AIMEDBIO set the offering price at the top end of the price band, 11,000 won. The overall lock-up commitment rate was 80.2%, with more than 50% committed for three months or longer.
Meanwhile, AIMEDBIO successfully executed large-scale technology transfers of its ADC candidate substances to Biohaven in the United States and Boehringer Ingelheim in Germany.
The company also signed a joint development and license agreement for its core pipeline with SK Plasma. Additionally, it participated as a joint development partner in the 'ADC Toolbox Program' with Samsung Biologics, achieving over 3 trillion won in technology transfer and joint development contracts solely during its unlisted phase.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
